Arletta Pharma Solutions — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Arletta Pharma Solutions is a clinical-stage biotech addressing the significant unmet medical need in women's sexual health, specifically HSDD and FSIAD. The company's core asset is Lybrido, a combination therapy in Phase II development, which has shown statistically and clinically relevant improvements in clinical studies. Operating from Amsterdam, Arletta positions itself as a specialist in a niche but substantial market where treatment options for women lag decades behind those for men. The company is actively engaged in the scientific community, presenting data at major sexual medicine conferences.

Women's HealthSexual Dysfunction

Technology Platform

Neurobiologically-informed combination therapy targeting sexual excitation and inhibition pathways.

Opportunities

The significant unmet medical need in female sexual dysfunction, with treatment options lagging over 20 years behind men's, presents a multi-billion dollar market opportunity.

Growing societal and medical acceptance of FSD as a treatable condition could accelerate market adoption.

A successful, differentiated product like Lybrido could position the company as a leader in a specialized niche.

Risk Factors

High clinical and regulatory risk due to the subjective endpoints and historical challenges in FSD drug development.

Commercialization risk includes potential payer resistance, physician education barriers, and stigma.

Pipeline concentration risk, with the company's value heavily dependent on the success of a single asset, Lybrido.

Competitive Landscape

The landscape includes FDA-approved drugs Addyi (flibanserin) and Vyleesi (bremelanotide), which have established a market but face limitations in efficacy and tolerability. Other biopharma companies are actively developing pharmacological and digital therapeutic solutions for FSD. Arletta's competition is defined by both existing products and novel mechanisms in clinical development.

More companies in Small Molecule Drugs →More companies in Netherlands →